1. Introduction {#s1}
===============

Chronic heart failure (CHF), commonly the end-stage of cardiovascular diseases, is highly prevalent in aging populations worldwide and is becoming a significant health care burden in developed countries.[@b1] The prevalence of other diseases such as atrial fibrillation (AF) is common in elderly patients with heart failure. To target rational diagnosis, therapy, and prognosis monitoring to the most appropriate patients, simple and readily available biomarkers are needed for these patients. Such biomarkers should independently predict outcome, and the more widely available these variables are, the more likely the biomarker will be adopted into routine clinical practice.

Brain natriuretic peptide (BNP) is mainly secreted by the heart and released into the circulation in response to increased wall stretch due to increased volume and pressure overload of the heart.[@b2] Currently, the measurement of BNP and its biologically inactive N-terminal fragment (NT-proBNP) are viewed as the most powerful prognostic biomarkers available in heart failure.[@b3]--[@b5] Therefore, every novel potential biomarker should be compared against these peptides.

The neutrophil-to-lymphocyte (N/L) ratio is a composite inflammatory biomarker that combines two different immune pathways: neutrophils are involved in active nonspecific inflammation, and lymphopenia is associated with physiological stress.[@b6] The N/L ratio has been associated with poor outcomes in patients with heart failure in several studies,[@b7],[@b8] but has not yet been compared against either BNP or NT-proBNP. In this study, we intended to demonstrate that the N/L ratio is independent of NT-proBNP as a prognostic biomarker in elderly patients with CHF.

2. Methods {#s2}
==========

2.1. Patients {#s2a}
-------------

We enrolled 1355 elderly patients (mean age, 72.6 ± 8.0 years) referred to the Department of Cardiology, Chinese PLA General Hospital (Beijing, China) with CHF between January 2011 and January 2014. Patients were included in the analysis if they had a diagnosis of CHF and total white blood cell (WBC) and differential counts and NT-proBNP measurements were performed at the time of admission. The diagnosis of CHF was made according to the criteria of the European Society of Cardiology[@b9] by symptoms or signs, electrocardiogram, chest radiograph, and echocardiography. Patients were categorized on the basis of left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (HFrEF, LVEF \< 40%), heart failure with mid-range ejection fraction (HFmrEF, 40% ≤ LVEF ≤ 49%), and heart failure with preserved ejection fraction (HFpEF, LVEF ≥ 50%) groups. Of the 1355 patients, 339 (25.0%), 375 (27.7%), and 641 (47.3%) patients were in the HFrEF, HFmrEF, and HFpEF group, respectively. The N/L ratio was calculated as the ratio of the neutrophils to lymphocytes from the differential counts. All referred patients had complete medical records, including demographic variables, laboratory values, echocardiographic parameters and information on past medical history and medications.

Patients with known evidence of acute myocardial ischemia, hematological diseases, a history of cancer and/or chemotherapy treatment, infection, chronic inflammatory conditions, glucocorticoid therapy and/or a history of glucocorticoid use three months before admission, which could affect the total white blood cell (WBC) and differential counts, were excluded. After a median follow-up period of 18 months (interquartile range 12 to 29), major cardiovascular events (MCE), including cardiac death and rehospitalization for heart failure, were documented through telephone follow-up and the hospital\'s medical records. All subjects provided informed consent. This study was approved by the Ethical Committee for Medical Research of Chinese PLA General Hospital and was conducted in accordance with the Helsinki Declaration.

2.2. Statistical analysis {#s2b}
-------------------------

Data analysis was performed using the Statistical Package for Social Sciences (SPSS 19.0). All continuous variables are given as the means ± SD, whereas discrete variables are presented as frequency counts and percentages. The continuous variables were compared between the MCE and non-MCE group using Student\'s *t*-tests and Mann-Whitney *U* tests for variables with normal and skewed distributions, respectively. The discrete variables were compared between the MCE and non-MCE group using the Chi-square test. A Spearman correlation test was employed to study the variables related to NT-proBNP levels and the N/L ratio. A multivariate logistic regression model was used to analyze the variables associated with AF. Odds ratio (OR) with 95% confidence intervals (CIs) were calculated. We used receiver operating characteristic (ROC) curves based on a univariate model to examine the power of NT-proBNP levels and the N/L ratio to predict MCE. The Kaplan-Meier method was used to assess the cumulative survival for MCE, and the log-rank test was used to compare differences among tertiles of NT-proBNP levels and the N/L ratio. Univariate and multivariate Cox regression models using tertiles of both variables were constructed to explore the relationship between the variables and outcome. The hazard ratios (HRs) with their 95% CIs were recorded. The variables for which a *P* value \< 0.1 was obtained in the univariate analysis were considered for use in the multivariate model. A *P* value of less than 0.05 was considered significant.

3. Results {#s3}
==========

3.1. Patient demographics {#s3a}
-------------------------

The clinical characteristics of the total 1355 patients in the study cohort and a comparison of the baseline characteristics of patients who experienced MCE with those who did not are shown in [Table 1](#jgc-14-02-127-t01){ref-type="table"}. More male (60.2%) elderly patients with CHF (mean age, 72.6 ± 8.0 years) were included in this study. The basic diseases of CHF were mostly hypertension (74.6%) and coronary artery disease (CAD) (77.7%). Beta-blockers (74.0%), nitrates (63.8%), aspirin (70.7%), and statins (78.4%) were the main drugs used by the patients.

###### Characteristics for the total study cohort and comparisons between patients that had MCE and those did not have them during the follow-up period.

                                           Total cohort (*n* = 1355)   MCE (*n* = 422)   Non-MCE (*n* = 933)   *P* value
  --------------------------------------- --------------------------- ----------------- --------------------- -----------
  Age, yrs                                        72.6 ± 8.0             73.9 ± 8.2          71.9 ± 7.8        \< 0.001
  Male                                               60.2%                  66.4%               57.4%            0.002
  Body mass index, kg/m^2^                        24.8 ± 3.8             24.7 ± 3.9          24.8 ± 3.8          0.544
  Systolic blood pressure, mmHg                  135.2 ± 20.4           134.7 ± 20.3        135.4 ± 20.5         0.547
  Diastolic blood pressure, mmHg                  75.3 ± 12.3            74.1 ± 12.7         75.8 ± 12.1         0.020
  Heart rate, bpm                                 77.4 ± 15.6            77.3 ± 14.7         77.5 ± 16.0         0.762
  Hypertension                                       74.6%                  75.1%               74.4%            0.774
  Coronary artery disease                            77.7%                  82.0%               75.8%            0.011
  Diabetes mellitus                                  36.1%                  38.2%               35.2%            0.288
  Atrial fibrillation                                51.1%                  44.8%               54.0%            0.002
  Renal failure                                      34.4%                  48.8%               27.9%          \< 0.001
  Total protein, g/L                              66.8 ± 6.2             66.9 ± 6.4          66.8 ± 6.1          0.664
  Albumin, g/L                                    39.2 ± 4.1             38.8 ± 4.1          39.4 ± 4.1          0.022
  Blood urea nitrogen, mmol/L                      7.4 ± 3.9              8.5 ± 4.8           6.9 ± 3.3        \< 0.001
  Creatinine, umol/L                              97.2 ± 50.9           110.1 ± 59.7         91.4 ± 45.3       \< 0.001
  eGFR, mL·min^−1^ per 1.73 m^−2^                 68.2 ± 21.3            61.7 ± 22.4         71.1 ± 20.1       \< 0.001
  Sodium, mmol/L                                  140.6 ± 3.9            140.1 ± 3.9         140.7 ± 3.9         0.009
  Cholesterol, mmol/L                              3.9 ± 1.0              3.8 ± 1.0           3.9 ± 1.0          0.064
  Hemoglobin, g/L                                129.8 ± 19.8           127.1 ± 20.9        131.1 ± 19.2         0.001
  White blood cell, 10^9^/L                        6.5 ± 2.2              6.5 ± 2.2           6.5 ± 2.2          0.618
  Platelets, 10^9^/L                             185.7 ± 56.5           180.1 ± 54.7        188.3 ± 57.2         0.013
  Mean platelet volume, fL                        10.7 ± 1.2             10.7 ± 1.3          10.7 ± 1.2          0.903
  NT-proBNP, pg/mL                              3199.0 ± 5299.7        4196.0 ± 5837.9     2748.0 ± 4975.6     \< 0.001
  Neutrophil/lymphocyte                            3.2 ± 3.1              3.6 ± 3.1           3.0 ± 3.0          0.004
  Left ventricular ejection fraction, %           48.1 ± 11.7            45.7 ± 12.0         49.1 ± 11.4       \< 0.001
  ACEIs                                              30.8%                  29.9%               31.2%            0.623
  Angiotensin II receptor blockers                   33.0%                  34.1%               32.5%            0.550
  Calcium-channel blockers                           44.5%                  43.6%               44.9%            0.654
  Beta-blockers                                      74.0%                  76.8%               72.8%            0.120
  Spironolactone                                     45.9%                  56.9%               40.9%          \< 0.001
  Other diuretics                                    45.5%                  56.9%               40.3%          \< 0.001
  Digoxin                                            28.7%                  37.0%               25.0%          \< 0.001
  Nitrates                                           63.8%                  68.0%               61.8%            0.029
  Aspirin                                            70.7%                  71.8%               70.2%            0.550
  Clopidogrel                                        50.2%                  50.7%               49.9%            0.794
  Warfarin                                           15.4%                  12.3%               16.8%            0.033
  Statins                                            78.4%                  78.2%               78.5%            0.915
  Length of stay, days                            11.3 ± 8.6             12.3 ± 7.8          10.9 ± 8.9          0.004
  NYHA class III/IV                                  36.3%                  51.9%               29.2%          \< 0.001

Data are expressed as mean ± SD or %. ACEIs: angiotensin-converting enzyme inhibitors; eGFR: estimated glomerular filtration rate; MCE: major cardiovascular events; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class III/IV: New York Heart Association heart failure class III/IV.

Patients with MCE were more likely to be older and male and to have lower diastolic blood pressure, CAD, atrial fibrillation (AF), and renal failure. Albumin, sodium, hemoglobin (Hb), and platelet levels and the estimated glomerular filtration rate (eGFR) were lower in patients who experienced MCE, whereas blood urea nitrogen (BUN) and creatinine levels were higher. More patients who experienced MCE were receiving spironolactone, other diuretics, digoxin, and nitrates, but only 12.3% of the patients with MCE were on a warfarin, compared with 16.8% of the patients without MCE. In addition, patients who experienced MCE had worse CHF at baseline, as indicated by a lower LVEF, a higher HYHA class, and longer hospital stays.

NT-proBNP levels and the N/L ratio were significantly higher in patients who had MCE. ROC curves examining the power of NT-proBNP and the N/L ratio to predict MCE are shown in [Figure 1](#jgc-14-02-127-g001){ref-type="fig"}. The areas under the curve were 0.628 (*P* \< 0.001, 95% CI: 0.596--0.660) and 0.582 (*P* \< 0.001, 95% CI: 0.549--0.615), respectively.

The prognoses of heart failure with reduced, mid-range and preserved ejection fraction are shown in [Table 2](#jgc-14-02-127-t02){ref-type="table"}. Patients with HFmrEF and HFpEF had a better prognosis than those with HFrEF.

![ROC curves based on a univariate model examining the power of N-terminal pro-brain natriuretic peptide and N/L ratio to predict major cardiovascular events.\
The areas under the curve were 0.628 (*P* \< 0.001, 95% CI: 0.596--0.660) and 0.582 (*P* \< 0.001, 95% CI: 0.549--0.615). BNP: brain natriuretic peptide; N/L ratio: neutrophil-to-lymphocyte ratio; ROC: receiver operating characteristic.](jgc-14-02-127-g001){#jgc-14-02-127-g001}

###### Prognoses of heart failure with reduced, mid-range and preserved ejection fraction.

             HFrEF   HFmrEF   HFpEF   *P* value
  --------- ------- -------- ------- -----------
  MCE        45.1%   26.7%    26.4%   \< 0.001
  Non-MCE    54.9%   73.3%    73.6%   \< 0.001

HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; MCE: major cardiovascular events.

3.2. The results of the Spearman correlation test {#s3b}
-------------------------------------------------

The results of the Spearman correlation test are shown in [Table 3](#jgc-14-02-127-t03){ref-type="table"}. The N/L ratio and NT-proBNP exhibited a positive correlation (*r* = 0.274, *P* \< 0.001). The N/L ratio was positively correlated with age, heart rate, BUN, creatinine, WBC and length of stay. This measurement was also positively correlated with being male; cigarette smoking; a history of diabetes mellitus or renal failure; the use of spironolactone, other diuretics or digoxin; and HYHA class. The N/L ratio was negatively correlated with body mass index (BMI), total protein, albumin, eGFR, sodium, cholesterol, Hb and LVEF. The N/L ratio was also negatively correlated with the use of aspirin and statins. Higher NT-proBNP levels were associated with increased age, heart rate, BUN, creatinine, WBC, mean platelet volume, and length of stay; worse HYHA status; a history of diabetes mellitus or renal failure; and the use of spironolactone, other diuretics or digoxin. The peptide\'s levels were lower in patients with a higher BMI, systolic blood pressure, total protein, albumin, eGFR, sodium, cholesterol, Hb, platelets and LVEF; subject history of AF; and the use of angiotensin II receptor blockers, calcium-channel blockers, aspirin or statins.

###### Spearman correlation coefficients for N-terminal pro-brain natriuretic peptide and N/L ratio.

                                           NT-proBNP   *P* value   N/L ratio   *P* value
  --------------------------------------- ----------- ----------- ----------- -----------
  N/L ratio                                  0.274     \< 0.001        −           −
  Age, yrs                                   0.114     \< 0.001      0.156     \< 0.001
  Male                                      −0.018       0.505       0.185     \< 0.001
  BMI, kg/m^2^                              −0.200     \< 0.001     −0.085       0.002
  Systolic blood pressure, mmHg             −0.160     \< 0.001      0.010       0.723
  Heart rate, beats/min                      0.238     \< 0.001      0.093       0.001
  Diabetes mellitus                          0.086       0.002       0.084       0.002
  Atrial fibrillation                       −0.057       0.037       0.001       0.968
  Renal failure                              0.327     \< 0.001      0.190     \< 0.001
  Total protein, g/L                        −0.123     \< 0.001     −0.108     \< 0.001
  Albumin, g/L                              −0.318     \< 0.001     −0.202     \< 0.001
  Blood urea nitrogen, mmol/L                0.308     \< 0.001      0.190     \< 0.001
  Creatinine, μmol/L                         0.315     \< 0.001      0.193     \< 0.001
  eGFR, mL·min^−1^ per 1.73m^−2^            −0.347     \< 0.001     −0.161     \< 0.001
  Sodium, mmol/L                            −0.166     \< 0.001     −0.244     \< 0.001
  Cholesterol, mmol/L                       −0.109     \< 0.001     −0.090       0.001
  Hemoglobin, g/L                           −0.214     \< 0.001     −0.108     \< 0.001
  White blood cell, 10^9^/L                  0.065       0.017       0.312     \< 0.001
  Platelets, 10^9^/L                        −0.069       0.011      −0.052       0.056
  Mean platelet volume, fL                   0.102     \< 0.001     −0.023       0.387
  Left ventricular ejection fraction, %     −0.362     \< 0.001     −0.071       0.009
  Angiotensin II receptor blockers          −0.069       0.011      −0.018       0.505
  Calcium-channel blockers                  −0.113     \< 0.001      0.027       0.326
  Spironolactone                             0.342     \< 0.001      0.142     \< 0.001
  Other diuretics                            0.315     \< 0.001      0.146     \< 0.001
  Digoxin                                    0.287     \< 0.001      0.095     \< 0.001
  Aspirin                                   −0.076       0.005      −0.068       0.012
  Statins                                   −0.158     \< 0.001     −0.083       0.002
  Length of stay, days                       0.204     \< 0.001      0.163     \< 0.001
  NYHA class                                 0.419     \< 0.001      0.190     \< 0.001

BMI: body mass index; eGFR: estimated glomerular filtration rate; N/L ratio: neutrophil-to-lymphocyte ratio; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class: New York Heart Association heart failure class.

3.3. Risk factor of AF {#s3c}
----------------------

Variables associated with AF were analyzed using multivariate logistic regression ([Table 4](#jgc-14-02-127-t04){ref-type="table"}). On multivariate regression, NLR (OR: 1.079, 95% CI: 1.027--1.134, *P* = 0.003) was independently associated with AF in the elderly with CHF.

###### Effects of multiple variables on atrial fibrillation in multivariate logistic regression analysis.

  Variable                                   OR        95% CI       *P* value
  --------------------------------------- -------- --------------- -----------
  Age                                      1.056    1.035--1.077    \< 0.001
  Diastolic blood pressure, mmHg           1.013    1.000--1.026      0.047
  Heart rate, beats/min                    1.015    1.004--1.025      0.005
  Coronary artery disease                  0.489    0.325--0.735      0.001
  Diabetes mellitus                        0.640    0.475--0.864      0.004
  Neutrophil/lymphocyte                    1.079    1.027--1.134      0.003
  Cholesterol, mmol/L                      0.728    0.624--0.849    \< 0.001
  Hemoglobin, g/L                          1.018    1.010--1.026    \< 0.001
  Left ventricular ejection fraction, %    1.125    1.109--1.142    \< 0.001
  Clopidogrel                              0.548    0.400--0.752    \< 0.001
  Warfarin                                 12.030   6.453--22.426   \< 0.001

Adjusted for: age, gender, body mass index, diastolic blood pressure, heart rate, hypertension, coronary artery disease, diabetes mellitus, neutrophil-to-lymphocyte ratio, N-terminal pro-brain natriuretic peptide, creatinine, cholesterol, hemoglobin, platelets, left ventricular ejection fraction, length of stay, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blockers, spironolactone, other diuretics, nitrates, aspirin, clopidogrel, warfarin, statins, and New York Heart Association heart failure class.

3.4. Prognosis of CHF {#s3d}
---------------------

During a median follow-up period of 18 (interquartile range 12 to 29) months, MCE occurred in 422 patients (31.1%). Kaplan-Meier plots for NT-proBNP levels and the N/L ratio by tertiles are shown in [Figure 2A](#jgc-14-02-127-g002){ref-type="fig"} and [2B](#jgc-14-02-127-g002){ref-type="fig"}, respectively. In univariate analyses using the lowest tertile of the N/L ratio as a reference, the patients in the highest tertile demonstrated a higher risk of MCE (HR: 1.586, 95% CI: 1.243--2.025, *P* \< 0.001). The highest NT-proBNP tertile was also significantly associated with MCE (HR: 2.152, 95% CI: 1.671--2.772, *P* \< 0.001), compared with the lowest tertile. In a multivariable model using tertile of both variable, age; cholesterol and platelets levels; HYHA class; and a history of CAD, AF, and renal failure were also independent predictors of outcome. The highest tertile of the N/L ratio was significantly associated with MCE (HR: 1.407, 95% CI: 1.098--1.802, *P* = 0.007), compared with the lowest tertile. Similarly, the highest NT-proBNP tertile was also significantly associated with MCE (HR: 1.461, 95% CI: 1.104--1.934, *P* = 0.008), compared with the lowest tertile. No differences were observed between the intermediate and lowest tertiles in terms of MCE risk for either variable ([Table 5](#jgc-14-02-127-t05){ref-type="table"}).

![Kaplan--Meier plot for N-terminal pro-brain natriuretic peptide (A) and neutrophil-to-lymphocyte ratio by tertiles (B).\
(A): The highest N-terminal pro-brain natriuretic peptide tertile was significantly associated with MCE (HR: 2.152, 95% CI: 1.671--2.772, *P* \< 0.001); (B): The highest neutrophil-to-lymphocyte ratio tertile was significantly associated with MCE (HR: 1.586, 95% CI: 1.243--2.025, *P* \< 0.001). MCE: major cardiovascular events.](jgc-14-02-127-g002){#jgc-14-02-127-g002}

###### Univariate and multivariate Cox models using tertiles of N-terminal pro-brain natriuretic peptide and N/L ratio for major cardiovascular events.

  Variable                                      Univariate HR (95% CI)   *P* value   Multivariable HR (95% CI)   *P* value
  -------------------------------------------- ------------------------ ----------- --------------------------- -----------
  NT-proBNP (high *vs*. low tertile)             2.152 (1.671--2.772)    \< 0.001      1.461 (1.104--1.934)        0.008
  NT-proBNP (Intermediate *vs.* low tertile)     1.399 (1.073--1.824)      0.013       1.232 (0.940--1.616)        0.130
  N/L ratio (high *vs.* low tertile)             1.586 (1.243--2.025)    \< 0.001      1.407 (1.098--1.802)        0.007
  N/L ratio (Intermediate *vs.* low tertile)     1.178 (0.913--1.520)      0.207       1.051 (0.813--1.360)        0.704
  Age, yrs                                       1.028 (1.015--1.040)    \< 0.001      1.015 (1.002--1.028)        0.021
  Coronary artery disease                        1.433 (1.117--1.837)      0.005       1.435 (1.108--1.859)        0.006
  Atrial fibrillation                            0.743 (0.613--0.900)      0.002       0.772 (0.629--0.947)        0.013
  Renal failure                                  2.073 (1.713--2.510)    \< 0.001      1.525 (1.237--1.881)      \< 0.001
  Platelets, 10^9^/L                             0.998 (0.996--0.999)      0.008       0.998 (0.996--1.000)        0.013
  NYHA class                                     1.698 (1.494--1.930)    \< 0.001      1.369 (1.182--1.586)      \< 0.001
  left ventricular ejection fraction             0.981 (0.973--0.989)    \< 0.001      0.995 (0.984--1.006)        0.346

Adjusted for: age, gender, coronary artery disease, atrial fibrillation, renal failure, albumin, blood urea nitrogen, creatinine, estimated glomerular filtration rate, sodium, cholesterol, hemoglobin, platelets, left ventricular ejection fraction, diastolic blood pressure, length of stay, other diuretics, digoxin, warfarin, and New York Heart Association heart failure class. N/L ratio: neutrophil-to-lymphocyte ratio; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class: New York Heart Association heart failure class.

4. Discussion {#s4}
=============

In our study, patients with HFpEF had a better prognosis than those with HFrEF. But there are conflicting reports regarding the long-term outcomes of HFpEF. Some have shown better event rates in HFpEF,[@b10] while others have shown similar event rates between HFpEF or HFrEF.[@b11],[@b12] The multitude of concurrent issues also renders it more difficult to pinpoint heart failure as the cause of patients\' symptoms or mortality in HFpEF patients. Indeed, although classifying the mode of death is highly subjective, HFpEF patients are less likely than HFrEF to die from definite heart failure or cardiovascular disease in general.[@b13] The contribution of non-cardiovascular modes of death may also explain the inconsistent mortality rate found in different HFpEF studies in different populations with different comorbidities.

We found that in elderly patients with CHF, the N/L ratio is one of the important risk factors for AF, and it is independent of NT-proBNP as a prognostic biomarker and that the risk of MCE increases 1.407-fold when the patient N/L ratio is elevated to the highest tertile (median 4.10, interquartile range: 3.39--6.01).

We discovered that the N/L ratio was one of the important risk factors for AF in elderly patients with CHF. The prevalence of AF is increasing as the population ages. Inflammation, which is related to the initiation and maintenance of AF, plays a key role in AF.[@b14] Both the pre- and post-operative N/L ratios are associated with an increased risk of developing AF after CABG,[@b15] and the N/L ratio is predictor of AF recurrence after cardioversion with amiodarone.[@b16] Heart failure and AF often coexist and each condition can promote the other, with an associated increase in overall morbidity and mortality.[@b17] So a higher N/L ratio was associated with an increased risk of AF which may make the prognosis of heart failure become worse in the elderly with CHF.

Previous studies examining the effect of the N/L ratio on heart failure prognosis did not include comparisons with NT-proBNP. The predictive ability of BNP or NT-proBNP values has long been reported in patients with heart failure.[@b18],[@b19] One study confirmed that NT-proBNP values provided independent prognostic information in Chinese elderly and very elderly patients with CHF.[@b20] Therefore, an evaluation of the N/L ratio\'s performance as a prognostic biomarker in relation to that of BNP or NT-proBNP in elderly patients with CHF is necessary.

The N/L ratio is a composite inflammatory biomarker and has been associated with various cardiac and noncardiac diseases.[@b6],[@b21] Many studies in acute coronary syndromes have reported that increased outcome risk was observed in patients with higher N/L values.[@b22],[@b23] In recent years, the N/L ratio has also been studied in heart failure, especially in acute heart failure. The N/L ratio has been found to be a better predictor of long-term mortality in patients with acute decompensated heart failure, which was independent of the LVEF.[@b7] A higher N/L ratio has been found to be associated with an increased risk of in-hospital mortality in patients with acute heart failure.[@b24],[@b25] Additionally, in patients with advanced heart failure, elevated N/L ratios were also associated with increased mortality or heart transplantation risk.[@b8] However, little attention has been paid to the importance of the N/L ratio in the context of CHF. The N/L ratio has not yet been investigated in elderly patients with CHF and has not been compared with NT-proBNP levels.

As a systemic syndrome, CHF is known to activate the immune system and inflammatory responses and is thus characterized by elevated levels of pro-inflammatory cytokines in the circulation.[@b26],[@b27] Inflammation is important in the pathogenesis, progression, severity and prognosis of CHF, and inflammatory mediators participate in its pathophysiology in various ways such as by exerting a direct impact on cardiac myocytes, fibroblasts and β-adrenergic receptors, leading to hypertrophy, fibrosis and impaired cardiac contractility, respectively, and by inducing apoptosis through stimulation of the proper genes.[@b28],[@b29] Inflammatory markers such as IL-6 and TNF are associated with heart failure risk among elderly patients and may improve heart failure risk stratification.[@b30] The N/L ratio is a composite inflammatory biomarker that combines two different immune pathways: neutrophils are involved in active nonspecific inflammation, and lymphopenia is associated with physiological stress.[@b6] Our study also found that age, heart rate, smoking, creatinine levels and albumin levels were correlated with the N/L ratio; these factors are among the nine routinely available variables used in the Health Aging and Body Composition heart failure model for incident heart failure in the elderly.[@b31] Thus, the N/L ratio appears to be a potent risk marker for CHF in elderly patients.

4.1. Study limitations {#s4a}
----------------------

This study included some limitations. We estimated only the predictive power of variables at a single time point and cannot assess changes in these variables over time or the impact of these changes on CHF outcomes. Our study was based on a single center and restricted to hospitalized patients, which may have introduced bias. Therefore, our results may be difficult to generalize to all elderly patients with CHF. We did not have information on the components of MCE, including cardiac death and rehospitalization for heart failure. Because neutrophilia and lymphopenia are reported to be associated with increased mortality in acute coronary syndromes and heart failure,[@b32],[@b33] other works are needed to compare their prognostic power with that of the N/L ratio.

4.2. Conclusions {#s4b}
----------------

Our study demonstrated for the first time that the N/L ratio was one of the important risk factors for AF and it was an inexpensive and readily available marker in elderly patients with CHF. This measurement provides good prognostic value, even when compared with a relatively expensive NT-proBNP measurement. We believe that the N/L ratio has a strong potential as a useful future marker of CHF.
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